Comparison
CJC-1295 vs. Sermorelin
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Growth
Growth
CAS no.
no data
86168-78-7
Molecular weight
3647.3 g/mol
3358 g/mol
Half-life
144 h
0.2 h
Sequence
YADAIFTNSYRKVLGQLSARKLLQDIMSR-DACYADAIFTNSYRKVLGQLSARKLLQDIMSRMechanism of action
CJC-1295
Synthetic analogue of growth-hormone-releasing hormone (GHRH), modified for extended half-life via a Drug Affinity Complex (DAC) binding to albumin. Acts on the pituitary GHRH receptor and stimulates endogenous growth-hormone release.
Sermorelin
Synthetic analogue of the first 29 amino acids of human growth-hormone-releasing hormone (GHRH). Stimulates pulsatile endogenous growth-hormone secretion from the pituitary via the GHRH receptor. Very short plasma half-life — pharmacodynamic effect lasts several hours nevertheless.
Evidence base
Highest evidence
Human trial
Human RCT
Studies
3
5
of which in humans
2
3
Effects recorded
3
3
Open conflicts
1
1
Documented adverse events
3
3